Cansortium Inc. (OTCMKTS:CNTMF) is a vertically integrated medical cannabis company primarily serving the Florida market. The company holds multiple state licenses for cultivation, processing, distribution and retail sale of medical cannabis products. Through its network of dispensaries, Cansortium provides a range of patient services including in-store consultations, home delivery and telehealth support to certified medical marijuana patients.
Cansortium’s product portfolio includes flower, pre-rolls, tinctures, capsules, topicals and vaporizable oils. The company markets proprietary brands such as The+™, offering high-potency THC formulations, and has entered into branded partnerships to develop specialty edibles and wellness items. All products are manufactured in Cansortium’s state-of-the-art processing facility, where quality control and consistency are monitored under rigorous regulatory standards.
Since its founding in 2015, Cansortium has expanded its operations in response to Florida’s evolving medical cannabis program. The company opened its first dispensary in 2016 and has steadily grown its footprint to support several thousand registered patients. Investment in cultivation infrastructure and research initiatives has positioned Cansortium to pursue opportunities in emerging U.S. cannabis markets and to adapt to new regulatory developments.
Cansortium was established by Abner Kurtin, who serves as chief executive officer, and is backed by a management team with expertise in biotechnology, pharmaceutical manufacturing and retail operations. The company emphasizes compliance, patient safety and product innovation to meet the needs of Florida’s medical cannabis community and to maintain its leadership position in a competitive industry.
AI Generated. May Contain Errors.
